Answer
Tagrisso (osimertinib mesylate) can prolong the QTc interval, potentially increasing the risk of ventricular tachyarrhythmias, including torsade de pointes, or sudden death.
Sources for this answer
- Tagrisso 40 mg film-coated tabletsAstraZeneca UK Limited · emc · SmPC §4.4 Special warnings and precautions for use · Version 32Document updated
Sources checked